November 21, 2016 - By Adrian Mccoy · 0 Comments
Bioanalytical Systems Inc (NASDAQ:BASI) institutional sentiment increased to 4 in Q2 2016. Its up 3.29, from 0.71 in 2016Q1. The ratio improved, as 5 hedge funds increased or opened new holdings, while 7 sold and reduced their equity positions in Bioanalytical Systems Inc. The hedge funds in our partner’s database now have: 232,433 shares, down from 235,863 shares in 2016Q1. Also, the number of hedge funds holding Bioanalytical Systems Inc in their top 10 holdings was flat from 0 to 0 for the same number . Sold All: 3 Reduced: 4 Increased: 3 New Position: 2.
Bioanalytical Systems, Inc. is a contract research organization (CRO) providing drug discovery and development services and analytical instruments. The company has a market cap of $5.27 million. The Firm operates through two divisions: contract research services and research products. It currently has negative earnings. The Company’s contract research services segment provides research and development support on a contract basis directly to pharmaceutical companies.
About 328 shares traded hands. Bioanalytical Systems, Inc. (NASDAQ:BASI) has declined 35.24% since April 19, 2016 and is downtrending. It has underperformed by 39.10% the S&P500.
Analysts await Bioanalytical Systems, Inc. (NASDAQ:BASI) to report earnings on December, 15.
According to Zacks Investment Research, “Bioanalytical Systems, Inc. is a contract research organization providing research and development resources to many of the leading pharmaceutical, medical device and biotechnology companies in the world. The company offers an efficient, variable-cost alternative to its clients’ internal product development, compliance and quality control programs. The company provides a broad array of value-added services and products focused on chemical analysis, allowing its clients to perform their research and development functions either in-house or at the company.”
Acadian Asset Management Llc holds 0% of its portfolio in Bioanalytical Systems, Inc. for 1,110 shares. Barclays Plc owns 83 shares or 0% of their US portfolio. Moreover, Blackrock Fund Advisors has 0% invested in the company for 1,075 shares. The Illinois-based Citadel Advisors Llc has invested 0% in the stock. Dimensional Fund Advisors Lp, a Texas-based fund reported 53,411 shares.#img1#
Insider Transactions: Since January 1, 0001, the stock had 1 buying transaction, and 0 sales for $389 net activity.
Bioanalytical Systems, Inc., incorporated on July 17, 1975, is an international contract research organization providing drug discovery and development services and analytical instruments. The Company’s clients and partners include pharmaceutical, biotechnology, academic and government organizations. The Firm derives its revenues from sales of its research services and drug development tools. The Firm supports the preclinical and clinical development needs of researchers and clinicians for small molecule and biomolecule drug candidates. The Company’s principal clients are scientists engaged in analytical chemistry, drug safety evaluation, clinical trials, drug metabolism studies, pharmacokinetics and basic research from small start-up biotechnology companies to many of the global pharmaceutical companies. The Firm operates in two business divisions: contract research services and research products, both of which addresses the bioanalytical, preclinical, and clinical research needs of drug developers.
More recent Bioanalytical Systems, Inc. (NASDAQ:BASI) news were published by: Marketwatch.com which released: “Bioanalytical Systems Inc.” on December 21, 2009. Also Seekingalpha.com published the news titled: “Bioanalytical Systems’ (BASI) CEO Jacqueline Lemke on Q3 2016 Results …” on August 12, 2016. Streetinsider.com‘s news article titled: “Bioanalytical Systems (BASI) Adds Alba Therapeutics CEO as Director” with publication date: December 14, 2015 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Adrian Mccoy